The stock of KalVista Pharmaceuticals Inc. (NASDAQ:KALV) last traded at $7.44, up 5.38% from the previous session.
KALV stock price is now 28.32% away from the 50-day moving average and -24.96% away from the 200-day moving average. The market capitalization of the company currently stands at $240.83M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target of $30, H.C. Wainwright recently initiated with Buy rating for KalVista Pharmaceuticals Inc. (NASDAQ: KALV). On July 29, 2019, SVB Leerink recently initiated its ‘Outperform’ rating on the stock quoting a target price of $31, while ‘Needham’ rates the stock as ‘Buy’.
In other news, Yea Christopher, Chief Development Officer sold 1,139 shares of the company’s stock on Nov 18. The stock was sold for $6,196 at an average price of $5.44. Upon completion of the transaction, the Chief Development Officer now directly owns 34,232 shares in the company, valued at $0.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 18, CFO, CBO & Secretary Palleiko Benjamin L sold 722 shares of the business’s stock. A total of $3,928 was realized by selling the stock at an average price of $5.44. This leaves the insider owning 68,390 shares of the company worth $0.51 million. Insiders disposed of 27,642 shares of company stock worth roughly $0.21 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KALV stock. A new stake in KalVista Pharmaceuticals Inc. shares was purchased by DRIEHAUS CAPITAL MANAGEMENT LLC during the first quarter worth $3,939,000. EVENTIDE ASSET MANAGEMENT, LLC invested $2,055,000 in shares of KALV during the first quarter. In the first quarter, AFFINITY ASSET ADVISORS, LLC acquired a new stake in KalVista Pharmaceuticals Inc. valued at approximately $717,000. POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in KALV for approximately $430,000. WALLEYE TRADING LLC purchased a new stake in KALV valued at around $121,000 in the second quarter. In total, there are 145 active investors with 88.08% ownership of the company’s stock.
With an opening price of $7.15 on Friday morning, KalVista Pharmaceuticals Inc. (NASDAQ: KALV) set off the trading day. During the past 12 months, KalVista Pharmaceuticals Inc. has had a low of $4.12 and a high of $17.34. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 13.40, and a quick ratio of 13.40. The fifty day moving average price for KALV is $5.84 and a two-hundred day moving average price translates $9.88 for the stock.
The latest earnings results from KalVista Pharmaceuticals Inc. (NASDAQ: KALV) was released for Jul, 2022.
KalVista Pharmaceuticals Inc.(KALV) Company Profile
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
